A-101

DRUG4 trials

Sponsors

Aclaris Therapeutics, Inc.

Conditions

Common WartSeborrheic Keratosis

Phase 2

Study of A-101 for the Treatment of Seborrheic Keratosis

CompletedNCT02260180

Aclaris Therapeutics, Inc.Seborrheic Keratosis

Start: 2014-10-31End: 2015-03-31Updated: 2020-12-02

A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis

CompletedNCT03148691

Aclaris Therapeutics, Inc.Seborrheic Keratosis

Start: 2017-05-17End: 2018-04-03Updated: 2019-05-06

Phase 3

Study of A-101 Topical Solution for the Treatment of Common Warts

CompletedNCT03687372

Aclaris Therapeutics, Inc.Common Wart

Start: 2018-09-17End: 2019-09-06Updated: 2020-10-05

Safety Study of A-101 Topical Solution for the Treatment of Common Warts

CompletedNCT03812510

Aclaris Therapeutics, Inc.Common Wart

Start: 2019-02-07End: 2019-12-20Updated: 2020-11-23